Cargando…
The evolving treatment paradigm in myelofibrosis
Myelofibrosis (MF) is a BCR–ABL1-negative myeloproliferative neoplasm diagnosed de novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV). Average survival of a patient with MF is 5–7 years. Disease complications include fatigue, early satiety, pruritus, painful splenic infa...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Informa Healthcare
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545544/ https://www.ncbi.nlm.nih.gov/pubmed/22793267 http://dx.doi.org/10.3109/10428194.2012.710905 |